Phase II evaluation of docetaxel plus one‐day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer

• Publication date

  2002-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.10350PMID 11920502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Statistics, 2001

  2001cited by this paper
• Paclitaxel and anthracycline combination chemotherapy for metastatic breast cancer

  1999cited by this paper
• Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

  1999cited by this paper
• A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.

  1999cited by this paper
• Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.

  1999influential reference
• Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.

  1999cited by this paper
• Clinical radiosensitization: why it does and does not work.

  1999cited by this paper
• Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.

  1999cited by this paper
• Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.

  1999cited by this paper
• A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.

  1999cited by this paper
• Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.

  1999cited by this paper
• Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.

  1999influential reference
• Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.

  1997cited by this paper
• Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines.

  1997cited by this paper
• Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.

  1995cited by this paper
• Hormonal therapy in the treatment of carcinoma of the prostate

  1995cited by this paper
• P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine.

  1994cited by this paper
• Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.

  1994cited by this paper
• Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.

  1993cited by this paper
• Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

  1992cited by this paper
• Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.

  1992cited by this paper
• Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.

  1992cited by this paper
• A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

  1989cited by this paper
• Cancer statistics

  1989cited by this paper
• Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group.

  1987cited by this paper
• Gonadotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma.

  1986cited by this paper
• Nuclear protein matrix as a target for estramustine‐induced cell death

  1986cited by this paper
• Use of estramustine phosphate in prostate cancer by the National Prostatic Cancer Project and by roswell park memorial institute.

  1984cited by this paper
• Review of the Veterans Administration Studies of Cancer of the Prostate and New Results Concerning Treatment of Stage I and II Tumours

  1980cited by this paper
• Statistical aspects of the analysis of data from retrospective studies of disease.

  1959cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Harnessing the Power of Traditional Chinese Medicine in Cancer Treatment: The Role of Nanocarriers

  2025cites this paper
• Theranostic inorganic-organic hybrid nanoparticles with a cocktail of chemotherapeutic and cytostatic drugs.

  2023cites this paper
• Galactosylated TPGS Micelles for Docetaxel Targeting to Hepatic Carcinoma: Development, Characterization, and Biodistribution Study

  2020cites this paper
• Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer

  2019cites this paper
• Thalidomide

  2018cites this paper
• Actual role and perspectives in the treatment of hormone refractory prostatic cancer

  2017cites this paper
• Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer

  2016cites this paper
• Design, fabrication, and characterization of a magnetic porous pdms as an on-demand drug delivery device

  2016cites this paper
• Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer.

  2015cites this paper
• Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.

  2014cites this paper
• SOY MEN ’ S HEALTH

  2014cites this paper
• Evaluation of inhibitory effect of melatonin on gastric adenocarcinoma AGS and MKN45 cell lines

  2013cites this paper
• Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study

  2013cites this paper
• Thalidomide: chemistry, therapeutic potential and oxidative stress induced teratogenicity.

  2012cites this paper
• The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.

  2012cites this paper
• Clinical development of novel therapeutics for castration‐resistant prostate cancer

  2012cites this paper
• Biochemical Pathways in Cancer

  2012cites this paper
• CYTOTOXITY EVALUATION OF DOCETAXEL NANOPARTICLES BY CULTURING HEPG2 CARCINOMA CELL LINES

  2012cites this paper
• Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells

  2012cites this paper
• [Long-term disease stabilization by docetaxel plus estramustine for castration-resistant prostate cancer : report of a case].

  2011cites this paper
• A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.

  2011cites this paper
• Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates.

  2011cites this paper
• The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model.

  2010cites this paper
• [Chemotherapy with low-dose docetaxel and estramustine phosphate in patient with liver dysfunction due to liver metastases of hormone-refractory prostate cancer : a case report].

  2010cites this paper
• Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer

  2010cites this paper
• Combination therapy with VP16 and ethinylestradiol for hormone-refractory prostate cancer: good response with tolerability.

  2010cites this paper
• Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone.

  2010cites this paper
• Molecular and traditional chemotherapy: a united front against prostate cancer.

  2010cites this paper
• Docetaxel‐based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival

  2009cites this paper
• Integrating Molecular Oncology into Therapeutic Strategies for Prostate Cancer

  2009cites this paper
• Systemic therapy and novel agents for metastatic castration resistant prostate cancer

  2009cites this paper
• Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial

  2009cites this paper
• The role of systemic cytotoxic therapy for prostate cancer

  2009cites this paper
• Interaction of the docetaxel with human serum albumin using optical spectroscopy methods

  2009cites this paper
• Evaluation of docetaxel plus estramustine in the treatment of patients with hormone‐refractory prostate cancer

  2009cites this paper
• A phase I/II trial of fixed-dose docetaxel plus irinotecan and escalating doses of estramustine phosphate for second-line or greater treatment of selected advanced solid tumors

  2009cites this paper
• Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients

  2009cites this paper
• Editorial Comment to docetaxel‐based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival

  2009cites this paper
• The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma.

  2009cites this paper
• Chemotherapy in patients with castration-resistant prostate cancer.

  2009cites this paper
• Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma.

  2009cites this paper
• Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.

  2008cites this paper
• Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.

  2008cites this paper
• Chemotherapie beim Prostatakarzinom

  2008cites this paper
• Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)

  2008influential citation
• Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience.

  2008cites this paper
• Chemotherapy in hormone-refractory prostate cancer.

  2008cites this paper
• Hormone-Refractory Prostate Cancer : Dynamically Modified Outcomes Analysis ( DYNAMO ) of a Randomized Controlled Trial

  2008cites this paper
• Docetaxel, with or without estramustine phosphate, as first‐line chemotherapy for hormone‐refractory prostate cancer: results of a multicentre, randomized phase II trial

  2008cites this paper
• Assessing outcomes in prostate cancer clinical trials

  2008cites this paper
• Multizentrische Therapieoptimierungsstudie zum Einsatz von Docetaxel (Taxotere®) und Mitoxantron (Novantron®) in der Therapie des hormonrefraktären Prostatakarzinoms

  2008cites this paper
• Efficacy and safety of docetaxel in the elderly

  2008cites this paper
• Chemotherapy in hormone‐refractory prostate cancer

  2008cites this paper
• Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients

  2008cites this paper
• Anticancer Effect of Combination Therapy of VP16 and Fosfesterol in Hormone-Refractory Prostate Cancer

  2008cites this paper
• Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparine in hormone-resistant prostate cancer patients

  2007cites this paper
• Cancer de la prostate

  2007cites this paper
• [Prostate cancer and chemotherapy].

  2007cites this paper
• A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.

  2007cites this paper
• Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer

  2007influential citation
• Taxane-Based Chemotherapy for Prostate Cancer

  2007cites this paper
• Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades

  2007cites this paper
• Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer

  2007cites this paper
• Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.

  2007cites this paper
• Urological cancers in clinical practice

  2007cites this paper
• Current indications for chemotherapy in prostate cancer patients.

  2007cites this paper
• Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone.

  2007cites this paper
• Estramustine Phosphate Based Chemotherapy for Hormone Refractory Prostate Cancer

  2007cites this paper
• Pre‐clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen‐independent prostate cancer

  2007cites this paper
• Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.

  2007cites this paper
• Docetaxel treatment in the elderly patient with hormone refractory prostate cancer

  2007cites this paper
• Changing perspectives of the role of chemotherapy in advanced prostate cancer.

  2006cites this paper
• Phase II trial evaluating a docetaxel‐capecitabine combination as treatment for hormone‐refractory prostate cancer

  2006cites this paper
• Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone‐releasing hormone analog AN‐207

  2006cites this paper
• An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels.

  2006cites this paper
• Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.

  2006cites this paper
• Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone‐refractory prostate cancer

  2006cites this paper
• A randomized study of docetaxel and dexamethasone with low‐ or high‐dose estramustine for patients with advanced hormone‐refractory prostate cancer

  2006cites this paper
• Hormone refractory prostate cancer: Management and advances.

  2006cites this paper
• Evaluation of Combined 177Lu-DOTA-8-AOC-BBN (7-14)NH2 GRP Receptor-Targeted Radiotherapy and Chemotherapy in PC-3 Human Prostate Tumor Cell Xenografted SCID Mice

  2006cites this paper
• Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model

  2006cites this paper
• Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis

  2006cites this paper
• Thromboembolism in Cancer Patients: Pathogenesis and Treatment

  2006cites this paper
• Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

  2006cites this paper
• Phase I/II Study of Weekly Docetaxel and Vinblastine in the Treatment of Metastatic Hormone‐Refractory Prostate Carcinoma

  2006cites this paper
• Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.

  2006cites this paper
• Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies

  2005cites this paper
• Present Status and Perspectives in the Treatment of Hormone-Refractory Prostate Cancer

  2005cites this paper
• Drug Insight: use of docetaxel in prostate and urothelial cancers

  2005cites this paper
• Advances in Prostate Cancer Chemotherapy: A New Era Begins 1

  2005cites this paper
• Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.

  2005cites this paper
• Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?

  2005cites this paper
• Chemotherapy in Prostate Cancer

  2005cites this paper
• [Prostate cancer: update].

  2005cites this paper
• New standards in the chemotherapy of metastatic hormone-refractory prostate cancer

  2005cites this paper
• Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.

  2005cites this paper
• Erkenntnisse und Ergebnisse einer prospektiven klinischen Phase II Studie zur Chemotherapie des hormonrefraktären Prostatakarzinoms mit PEG-liposomalen Doxorubicin (Caelyx R )

  2005cites this paper
• Future directions in the treatment of androgen-independent prostate cancer.

  2005cites this paper
• Update in Oncology

  2005cites this paper
• A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.

  2005cites this paper